This conference will provide updates on the latest advances in cancer care across a variety of disease sites. University of Cincinnati Cancer Center experts and three visiting keynote speakers will present their own research and highlights from the most recent American Society of Clinical Oncology (ASCO©) conference. 

The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to continual updates from ongoing clinical trials on recently approved and emerging treatment approaches. Clinicians therefore need to stay abreast with recent progress to enable improved outcomes for patients.This educational Clinical Clip will highlight important advances in RRMM based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies.This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd Amer...

Clinicians need to keep up with recent progress in low-risk myelodysplastic syndromes (MDS) to facilitate appropriate integration of newly approved and novel therapies.This educational Clinical Clip will highlight key updates in low-risk MDS based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

The impact of the ever-changing COVID-19 pandemic is creating a rapidly evolving clinical environment for healthcare providers (HCPs). As a result, HCPs are challenged to keep up with the most current clinical information, while constantly evolving their approaches to the management of anticoagulated patients with severe bleeding. Innovative approaches are required to educate these HCPs on how they can make a positive impact on patient care and improve clinical outcomes in the new COVID-19 world...

As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages, requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Over...

As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages, requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding, or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Ove...

As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages, requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding, or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Ove...

As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages, requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding, or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Ove...

As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages, requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding, or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Ove...